Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
| Industry | Market Weight | YTD Return | |
|---|---|---|---|
| All Industries | 100.00% | 8.49% | |
| Drug Manufacturers - General | 34.17% | 14.80% | |
| Healthcare Plans | 13.63% | 3.03% | |
| Biotechnology | 12.11% | 7.11% | |
| Medical Devices | 11.44% | -2.32% | |
| Diagnostics & Research | 11.42% | 8.40% | |
| Medical Instruments & Supplies | 6.67% | 9.24% | |
| Medical Care Facilities | 3.25% | 29.99% | |
| Drug Manufacturers - Specialty & Generic | 2.75% | -0.55% | |
| Medical Distribution | 2.34% | 13.15% | |
| Health Information Services | 2.09% | 11.37% | |
| Pharmaceutical Retailers | 0.15% | -53.66% | |
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
|---|---|---|---|---|---|---|---|
| 807.79 | 926.31 | 10.77% | Buy | ||||
| 566.75 | 616.08 | 7.72% | Buy | ||||
| 158.56 | 171.47 | 5.65% | Buy | ||||
| 127.78 | 143.28 | 4.79% | Buy | ||||
| 181.94 | 191.92 | 4.76% | Buy | ||||
| 604.12 | 629.42 | 3.41% | Buy | ||||
| 271.65 | 284.09 | 2.90% | Buy | ||||
| 104.77 | 124.23 | 2.70% | Buy | ||||
| 332.51 | 320.24 | 2.64% | Buy | ||||
| 30.72 | 31.73 | 2.58% | Hold |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 150.05 | 39.084B | 0.09% | ||
| 275.47 | 20.601B | 0.10% | ||
| 147.91 | 7.363B | 0.45% | ||
| 100.27 | 7.126B | 0.35% | ||
| 54.74 | 5.134B | 0.40% |
Mutual Fund Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 226.29 | 47.799B | 0.30% | ||
| 95.43 | 47.799B | 0.30% | ||
| 137.83 | 20.601B | 0.10% | ||
| 98.08 | 14.902B | 0.80% | ||
| 97.77 | 14.902B | 0.80% |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
Analyst Report: Tilray Brands, Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
RatingPrice TargetAnalyst Report: Hologic, Inc.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
RatingPrice TargetAnalyst Report: Revvity, Inc.
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
RatingPrice TargetAnalyst Report: HCA Healthcare, Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of June 2024, the firm owned and operated 188 hospitals, 123 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
RatingPrice Target

